According to the Wall Street Journal, the Food and Drug Administration will convene on Tuesday to discuss the future of GSK’s diabetes drug Avandia.
The battle could spark a change in the way the FDA responds to drug safety concerns and the pharmaceutical industry is concerned it may lead to a delay in drug approvals.
Studies have shown that Avandia, which is made by GlaxoSmithKline (GSK), has been linked to increased risk of heart attack.
The FDA’s own scientists have reservations about the agency’s drug divisions– they believe the agency demand too much evidence of a drugs dangers before approving it.
Read more on the Wall Street Journal website.